7Baggers
Quarterly
Annual
    Unit: USD2025-05-31 2025-02-28 2024-11-30 2024-08-31 2024-05-31 2024-02-29 2023-11-30 2023-08-31 2023-05-31 2023-02-28 2022-11-30 2022-08-31 2022-05-31 2022-02-28 2021-11-30 2021-08-31 2021-05-31 2021-02-28 2020-11-30 2009-08-31 
      
    		                    
      cash flows from operating activities
    		                    
      net income
    		-67,317,000 3,074,000 206,000 843,000 3,137,000 4,029,000 1,945,000 534,000 4,008,000 4,174,000 1,245,000 961,000 4,087,000 4,409,000 3,026,000 305,000 3,787,000 3,211,000 2,479,000 163,156 
      adjustments to reconcile net income to net cash from operating activities
    		                    
      depreciation and amortization
    		2,318,000 2,274,000 2,265,000 2,206,000 1,263,000 1,105,000 1,091,000 1,037,000 945,000 935,000 923,000 850,000 884,000 995,000 845,000 928,000 886,000 911,000 865,000  
      change in fair value of contingent consideration
    		0   -1,369,000 -600,000 440,000 -110,000              
      discharge of holdback obligation related to immunetrics acquisition
    		0                    
      amortization of investment discounts
    		-4,000 -21,000 -39,000 -31,000                 
      stock-based compensation
    		1,414,000 1,692,000 1,724,000 1,596,000 1,795,000 1,785,000 1,362,000 1,280,000 1,248,000 1,264,000 1,036,000 758,000 766,000 791,000 722,000 709,000 705,000 804,000 532,000 53,634 
      deferred income taxes
    		-7,174,000 -947,000 40,000 -399,000 -481,000 -497,000 -388,000 -749,000 -1,749,000   -224,000 -470,000 37,000 387,000 -544,000 -90,000 -41,000 47,000 -32,472 
      income from disposal of assets
    		                    
      impairments
    		                    
      currency translation adjustments
    		40,000 -26,000 -42,000 20,000 -56,000 -15,000 -54,000 -7,000 144,000 -22,000 52,000 -14,000 24,000 -38,000 -237,000 -137,000 40,000    
      increase in
    		                    
      accounts receivable
    		1,713,000 -3,689,000 -3,668,000 3,072,000 2,970,000 -2,768,000 -145,000 524,000 1,184,000 301,000 2,088,000 4,800,000 -3,548,000 -3,216,000 -1,972,000 3,111,000 -1,656,000 -3,975,000 91,000 680,861 
      prepaid income taxes
    		421,000 952,000 -130,000 -995,000 162,000 -1,327,000 767,000 -804,000 397,000 595,000 399,000 -1,069,000 127,000 135,000 428,000 -520,000 758,000 -690,000 410,000  
      prepaid expenses and other assets
    		-102,000 -332,000 708,000 -645,000 -328,000 345,000 -1,515,000 929,000 -363,000 199,000 -1,266,000 -127,000 -66,000 1,253,000 21,000 -94,000 -194,000 329,000 -141,000  
      accounts payable
    		457,000 86,000 518,000 -991,000 298,000 43,000 173,000 -213,000 7,000 112,000 13,000 -194,000 10,000 390,000 -368,000 90,000 -102,000 66,000 -15,000 -66,362 
      other liabilities
    		-1,864,000 3,359,000 -4,095,000 -746,000 -1,167,000 3,274,000 -2,129,000 671,000 1,171,000 -1,117,000 107,000          
      deferred revenue
    		998,000 115,000 1,235,000 -897,000 -1,020,000 -203,000 -440,000 -132,000 1,122,000 -1,014,000 200,000 781,000 842,000 556,000 34,000 -8,000 19,000 279,000 -56,000 39,857 
      net cash from operating activities
    		8,144,000 5,669,000 -1,274,000 1,664,000 5,684,000 5,810,000 162,000 3,060,000 8,548,000 5,541,000 4,707,000 7,927,000 3,794,000 2,597,000 3,582,000 8,273,000 4,296,000 1,301,000 5,333,000 875,929 
      capex
    		-297,000 -66,000 -86,000 -16,000 -117,000 0 0 -196,000 59,000 -207,000 -109,000 -79,000 -30,000 -149,000 -561,000 -661,000 -383,000 -378,000 -205,000 -9,783 
      free cash flows
    		7,847,000 5,603,000 -1,360,000 1,648,000 5,567,000 5,810,000 162,000 2,864,000 8,607,000 5,334,000 4,598,000 7,848,000 3,764,000 2,448,000 3,021,000 7,612,000 3,913,000 923,000 5,128,000 866,146 
      cash flows from investing activities
    		                    
      purchases of property and equipment
    		-297,000 -66,000 -86,000 -16,000 -117,000   -196,000 59,000 -207,000 -109,000 -79,000 -30,000 -149,000 -561,000 -661,000 -383,000 -378,000 -205,000 -9,783 
      purchase of short-term investments
    		-1,500,000 -1,500,000 -3,500,000 0 -18,170,000 -18,445,000 -30,544,000 -23,210,000 -24,679,000 -17,638,000 -29,518,000          
      proceeds from maturities of short-term investments
    		10,397,000 2,120,000 1,500,000 -4,000 34,841,000 21,474,000 14,778,000 32,900,000 33,856,000 24,013,000 24,138,000          
      proceeds from sales of investments
    		0   0                 
      purchase of long-term investments
    		                    
      purchased intangibles
    		-26,000 -156,000 -186,000 -33,000 -41,000 -220,000 -247,000 -82,000 -442,000 -38,000 -39,000          
      net working capital & excess cash settlement - pro-ficiency acquisition
    		0 0 -227,000                  
      capitalized computer software development costs
    		-767,000 -709,000 -639,000 -674,000 -801,000 -868,000 -851,000 -669,000 -875,000 -781,000 -894,000 -885,000 -759,000 -669,000 -838,000 -676,000 -799,000 -746,000 -728,000 -183,225 
      net cash from investing activities
    		7,807,000 684,000 -3,138,000 -99,500,000 69,913,000 -7,516,000 -16,864,000 520,000 7,919,000 5,349,000 -6,422,000 2,303,000 -17,087,000 17,138,000 1,951,000 -27,607,000 12,761,000 13,978,000 -25,874,000 -193,008 
      cash flows from financing activities
    		                    
      payment of dividends
    		   -1,202,000 -1,200,000 -1,198,000 -1,196,000 -1,196,000 -1,200,000 -1,195,000 -1,218,000 -1,214,000 -1,212,000 -1,211,000 -1,209,000 -1,208,000 -1,207,000 -1,201,000 -1,195,000  
      payments on contracts payable
    		0   0        0         
      proceeds from the exercise of stock options
    		7,000 28,000 288,000 257,000 164,000 146,000 164,000 8,000 572,000 205,000 758,000 198,000 152,000 169,000 372,000 49,000 576,000 656,000 180,000 34,554 
      net cash from financing activities
    		7,000 -1,548,000 288,000 -945,000 -3,536,000 -1,052,000 -1,032,000 -1,188,000 -628,000 -20,990,000 -460,000 -1,016,000 -4,727,000 -1,042,000 -837,000 -2,493,000 -631,000 -545,000 -1,015,000 -582,050 
      net increase in cash and cash equivalents
    		15,958,000   -98,781,000    2,392,000 15,839,000 -10,100,000 -2,175,000 9,214,000 -18,020,000 18,693,000 4,696,000 -21,827,000 16,426,000 14,734,000 -21,556,000 100,871 
      cash and cash equivalents, beginning of period
    		0 0 10,311,000 0 0                
      cash and cash equivalents, end of period
    		15,958,000 4,805,000 6,187,000 -98,781,000 72,061,000 -2,758,000 39,789,000 2,392,000 15,839,000 -10,100,000 49,392,000 9,214,000 -18,020,000 18,693,000 41,680,000 -21,827,000 16,426,000 14,734,000 27,651,000 100,871 
      supplemental disclosures of cash flow information
    		                    
      income taxes paid
    		404,000 504,000 112,000 1,475,000 1,072,000 3,046,000 96,000 1,645,000 1,466,000   1,232,000 1,080,000 898,000 23,000 964,000 15,000 821,000 57,000 171,906 
      supplemental disclosures of non-cash activities
    		                    
      measurement period adjustments
    		                    
      non-cash investing and financing activities
    		                    
      right of use assets capitalized
    		 0 451,000         0 0        
      unrealized gains on available-for-sale securities
    		  4,000                  
      net decrease in cash and cash equivalents
    		  -4,124,000   -2,758,000 -17,734,000              
      impairment of other intangibles
    		                    
      accrued income taxes
    		       -800,000             
      business acquisition, net of cash acquired
    		                    
      repurchase and retirement of common shares
    		       0 0            
      stock issued for acquisition of lixoft
    		                    
      creation of contract liabilities from acquisition of subsidiaries
    		                    
      amortization of investment (discounts) premiums
    		     -401,000 -395,000 -396,000 -359,000 -289,000 -90,000          
      cash and cash equivalents, beginning of year
    		      57,523,000 0 0 0 51,567,000 0 0 0 36,984,000 0 0 0 49,207,000 0 
      gain from disposal of assets
    		                    
      acquisition of immunetrics, net of cash acquired
    		                    
      change in value of contingent consideration
    		           0 40,000 122,000 121,000 122,000 121,000 122,000 121,000  
      amortization of investment premiums
    		           185,000 371,000 512,000 610,000 598,000     
      proceeds from sale of short-term investments
    		           33,189,000 29,122,000 30,743,000 16,067,000 32,161,000 37,118,000 24,932,000 6,018,000  
      cash used to acquire subsidiaries
    		                    
      cash received in acquisition
    		                    
      proceeds from follow-on public offering
    		                    
      creation of contract liabilities for acquisition of subsidiaries
    		                    
      accrued payroll and other incomes
    		            727,000 -1,747,000 -1,637,000 3,006,000 -293,000 591,000 49,000 26,578 
      purchases of short-term investments
    		            -45,420,000 -12,787,000 -12,717,000  -23,175,000 -9,830,000 -30,959,000  
      cash flows used in financing activities
    		                    
      revenue in excess of billings
    		              1,667,000      
      billings in excess of revenue
    		              -65,000      
      revenues in excess of billings
    		               733,000 -46,000 -1,000,000 256,000  
      billings in excess of revenues
    		               -10,000 -131,000 52,000 65,000  
      purchases of intellectual property
    		                    
      right-of-use assets capitalized
    		                    
      amortization of note premiums
    		                 646,000 630,000  
      cash flows used in investing activities
    		                    
      right of use assets acquired
    		                    
      stock issued for acquisition of cognigen corporation
    		                    
      depreciation and amortization of property and equipment
    		                   5,284 
      amortization of capitalized computer software development costs
    		                   138,025 
      amortization of intellectual property
    		                    
      shares issued to directors for services
    		                    
      accrued bonus
    		                    
      amortization of customer relationships
    		                   4,364 
      (income)/income from discontinued operations
    		                    
      excess tax benefits from share-based arrangement
    		                    
      (gain)/income from sale of assets
    		                    
      accounts receivable and contracts receivable
    		                    
      income tax refundable
    		                    
      inventory
    		                   49,464 
      net cash from operating activities of continuing operations
    		                    
      net cash from operating activities of discontinued operations
    		                    
      proceeds from sale of words+, inc.
    		                    
      proceeds from sale of assets
    		                    
      purchase of royalty
    		                    
      net cash from investing activities of continuing operations
    		                    
      net cash from investing activities of discontinued operations
    		                    
      repurchase of common stock
    		                   -616,604 
      net cash from financing activities of continuing operations
    		                    
      net increase in cash and cash equivalents from continuing operations
    		                    
      net increase in cash and cash equivalents from discontinued operations
    		                    
      interest paid
    		                    
      net cash (used in) financing activities of continuing operations
    		                    
      net (decrease) in cash and cash equivalents from discontinued operations
    		                    
      bad debts
    		                   0 
      gain on sales of property and equipment
    		                    
      accrued warranty and service costs
    		                   3,037 
      proceeds from sale of property and equipment
    		                    
      gain on sale of equipment
    		                    
      excess tax benefits from share-based arrangements
    		                    
      proceeds from sale of investments
    		                   0 
      other assets
    		                   -73,808 
      accrued bonuses to officers
    		                    
      investment in securities
    		                    
      adjustments to reconcile net income to net cash
    		                    
      provided by operating activities
    		                    
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.